As Biosimilar Revenues Fall, Amgen Looks To Next Wave For Growth
US Adalimumab Launch Looms As Other Pipeline Candidates See Success In Trials
As Amgen’s current biosimilars portfolio recedes, bigger opportunities are on the horizon in the next wave • Source: Shutterstock 
